alpha-aminopyridine has been researched along with Diabetes Mellitus in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abely, M; Bounyar, L; Chatron, E; Chiron, R; Cosson, L; Dominique, S; Durieu, I; Gerardin, M; Kessler, L; Kessler, R; Mankikian, J; Melly, L; Misgault, B; Porzio, M; Reynaud, Q; Ronsin-Pradel, O; Touzet, S; Troussier, F; Weiss, L | 1 |
| Chen, H; Chen, Z; Dong, H; Huang, C; Li, G; Li, X; Luo, D; Sun, L; Sun, S; Wei, S; Yang, H; Zhou, Y | 1 |
| Albrecht-Küpper, B; Dinh, W; Gheorghiade, M; Sabbah, HN; van der Laan, M; Voors, AA | 1 |
| Goff, D; Hammond, ME; Harrison, SD; Henriksen, EJ; Johnson, KW; Kinnick, TR; Ma, ST; Nuss, JM; Reeder, JW; Ring, DB; Samuels, I; Slabiak, T; Wagman, AS | 1 |
1 review(s) available for alpha-aminopyridine and Diabetes Mellitus
| Article | Year |
|---|---|
Partial Adenosine A1 Agonist in Heart Failure.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Aminopyridines; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Coronary Artery Disease; Diabetes Mellitus; Dipeptides; Drug Partial Agonism; Furans; Heart; Heart Failure; Humans; Insulin Resistance; Ischemic Preconditioning, Myocardial; Lipolysis; Mitochondria, Heart; Myocardium; Oxygen Consumption; Pyridines; Renal Insufficiency; Tachycardia, Supraventricular; Thiazoles | 2017 |
3 other study(ies) available for alpha-aminopyridine and Diabetes Mellitus
| Article | Year |
|---|---|
Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Blood Glucose; Child; Cystic Fibrosis; Diabetes Mellitus; Drug Administration Schedule; Drug Combinations; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Male; Middle Aged; Prospective Studies; Quinolones; Young Adult | 2020 |
Arg⁹⁷² insulin receptor substrate-1 inhibits endothelial nitric oxide synthase expression in human endothelial cells by upregulating microRNA-155.
Topics: Adult; Aged; Aminopyridines; Cells, Cultured; Diabetes Mellitus; Enzyme Activation; Female; Human Umbilical Vein Endothelial Cells; Humans; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; MicroRNAs; Middle Aged; Morpholines; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Transfection | 2015 |
Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo.
Topics: Aminopyridines; Animals; Biological Transport; CHO Cells; Cricetinae; Diabetes Mellitus; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Female; Gene Expression; Glucose; Glycogen Synthase; Glycogen Synthase Kinase 3; Hepatocytes; Humans; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptor, Insulin; Transfection | 2003 |